Since both Sur and NCL are overexpressed in a variety of cancers, the chimerization of NCL-APT with Sur_Dz for the development of a targeted therapeutic platform can be functional on a wide spectrum of cancer types. This evidence concerns the gene ABCC8 and cancer.